Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus.

• Main Authors: Mengliu Yang, Jing Dong, Hua Liu, Ling Li, Gangyi Yang
• Format: Article
• Language: English
• Published: Public Library of Science (PLoS) 2011-01-01
• Series: PLoS ONE
• Online Access: http://europepmc.org/articles/PMC3202531?pdf=render

BACKGROUND: To investigate the effects of short-term continuous subcutaneous insulin infusion (CSII) on plasma fibroblast growth factor-21 (FGF-21) levels in patients with newly diagnosed type 2 diabetes mellitus (nT2DM). METHOD: Sixty-eight patients with nT2DM (nT2DM group), and 52 gender-, age- and body mass index (BMI) -matched normal glucose tolerance (NGT group) controls participated in the study. 30 nT2DM patients with FBG ≥ 14.0 mmol/L were treated with CSII for 2 weeks, and were underwent a euglycemic-hyperinsulinemic clamp pre- and post-treatment. Plasma FGF-21 concentrations were measured with a commercial ELISA kit. The relationship between plasma FGF-21 levels and metabolic parameters was also analyzed. RESULTS: Fasting plasma FGF-21 levels were higher in the nT2DM group than in NGT groups (1.60 ± 0.08 vs. 1.13 ± 0.26 µg/L, P<0.01). In nT2DM patients, fasting plasma FGF-21 concentrations were significantly decreased after CSII treatment for 2 weeks (1.60 ± 0.08 vs.1.30 ± 0.05 µg/L, P<0.05), accompanied by a significant increase in the whole body glucose uptake (M value) and blood glucose control. The changes in plasma FGF-21 levels (ΔFGF-21) were positively associated with the amelioration of insulin resistance shown by the changes in M value. CONCLUSION: Plasma FGF-21 level is associated with whole body insulin sensitivity and significantly reduced following short-term CSII treatment.